Additional data: Adrie et al.

 

 

 

Baseline

after Solvent

NO 1 ppm

NO 5 ppm

NO 10 ppm

NO 20 ppm

PaO2 (mmHg)

66 ± 11

85 ± 14*

99 ± 20**

125 ± 22**

102 ± 26**

QVA/QT (%)

49.4 ± 2.1

45 ± 2.2

41.2 ± 3.9*

39.5 ± 3.3**

42.2 ± 3**

LAP (mmHg)

10 ± 1

10 ± 1

10 ± 1

10 ± 1

10 ± 1

CVP (mmHg)

9 ± 1

10 ± 1

10 ± 1

10 ± 1

9 ± 1

PAP (mmHg)

24 ± 1

23 ± 1*

20 ± 1**

20 ± 1*

22 ± 1

PVR (dynes·sec·cm-5)

384 ± 56

325 ± 60

250 ± 51*

276 ± 62*

320 ± 47

SAP (mmHg)

85 ± 10

85 ± 8.7

86 ± 12

86 ± 9

82 ± 12

SVR (dynes·sec·cm-5)

2111 ± 312

1989 ± 272

2168 ± 446

2160 ± 273

2160 ± 352

CO (l·min-1)

2.9 ± 0.2

3.2 ± 0.1

3.2 ± 0.3

2.9 ± 0.1

2.9 ± 0.3

cGMP (pmol·ml-1)

22.7 ± 1.8

30.5 ± 3.5

36.5 ± 2.7*

46 ± 12**

70 ± 22**

 

Supplemental Table 1. Effect of inhaled NO during solvent infusion on hemodynamics and gas exchange. Second dose response trials after solvent administration (n=5). Absolute value of arterial blood gas tensions (PaO2), venous admixture (QVA/QT), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and cardiac output (CO). cGMP: arterial plasma guanosine 3’,5’-cyclic monophosphate (n=3). Nitric oxide doses were administered in random order. * p<0.05, ** p<0.01 vs baseline.

 

 

Additional data: Adrie et al.

 

 

 

Baseline

after Zaprinast

NO 1 ppm

NO 5 ppm

NO 10 ppm

NO 20 ppm

PaO2 (mmHg)

70 ± 11

69 ± 16

67 ± 14

72 ± 12

71 ± 15

QVA/QT (%)

42.2 ± 4.5

42 ± 2.6

40.5 ± 3.2

44.6 ± 3.2

43.1 ± 4

LAP (mmHg)

10 ± 1

10 ± 1

10 ± 1

10 ± 1

10 ± 1

CVP (mmHg)

10 ± 1

10 ± 1

10 ± 1

10 ± 1

11 ± 1

PAP (mmHg)

19 ± 1

19 ± 1

19 ± 1

18 ± 1

19 ± 1

PVR (dynes·sec·cm-5)

190 ± 27

199 ± 24

193 ± 31

171 ± 24

198 ± 32

SAP (mmHg)

81 ± 3

78 ± 5

81 ± 5.5

85 ± 4

79 ± 6

SVR (dynes·sec·cm-5)

1512 ± 144

1440 ± 141

1384 ± 144

1424 ± 129

1440 ± 216

CO (l·min-1)

4 ± 0.2

3.9 ± 0.3

4.1 ± 0.4

4.4 ± 0.4

4.2 ± 0.5

cGMP (pmol·ml-1)

42.1 ± 7.5

70.8 ± 6.7*

81.4 ± 10.8**

94.5 ± 8.5**

104 ± 8.5**

Supplemental Table 2. Effect of inhaled NO during Zaprinast infusion on hemo-dynamics and gas exchange. Second dose response trials after Zaprinast administration (n=10). Absolute value of arterial blood gas tensions (PaO2), venous admixture (QVA/QT), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and cardiac output (CO). cGMP: arterial plasma guanosine 3’,5’-cyclic monophosphate (n=7). Nitric oxide doses were administered in random order. * p<0.05, ** p<0.01 vs baseline.